Telix, Kettering to research PSMA radiotracer

Kettering Health and Telix Pharmaceuticals have signed a deal to study Telix'...Read more on AuntMinnie.comRelated Reading: Lightpoint, Telix ink collaboration agreement Telix works with Merck on cancer therapies Telix Japan names COO Telix, Monrol reach agreement on therapeutic isotope supply ARTMS, Telix produce PSMA-11 in cyclotron
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news

Related Links:

New J. Chem., 2021, Accepted Manuscript DOI: 10.1039/D1NJ04407A, PaperYifan Zhang, Enrico Benassi, Yue Shi, Xuanyu Yue, Lin Cui, Shengchao Yang , Zhiyong Liu, Xuhong Guo Significant progress has been made in the application of nanoparticle drug carriers in the treatment of cancer. However, the clearance of nanoparticles by the reticuloendothelial system limits their circulation time... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - New J. Chem. latest articles - Category: Chemistry Authors: Source Type: research
Tumor-associated angiogenesis is a key target for anti-cancer therapy. The imbalance between pro-angiogenic and anti-angiogenic signals elicited by tumor cells or tumor microenvironment always results in activating “angiogenic switch”. Tumor angiogenesis functions in multi-aspects of tumor biology, including endothelial cell apoptosis, tumor metastasis, and cancer stem cell proliferation. Numerous studies have indicated the important roles of inexpensive and less toxic natural products in targeting tumor angiogenesis-associated cytokines and apoptotic signaling pathways. Our current knowledge of tumor angiogene...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Mol Biol Rep. 2021 Oct 20. doi: 10.1007/s11033-021-06752-9. Online ahead of print.ABSTRACTCancer immunotherapy is a rapidly evolving concept that has been given the tag "fifth pillar" of cancer therapy while radiation therapy, chemotherapy, surgery and targeted therapy remain the other four pillars. This involves the stimulation of the immune system to control tumor growth and it specifically targets the neoplastic cells rather than the normal cells. Conventional chemotherapy has many limitations which include drug resistance, recurrence of cancer and severe adverse effects. Immunology has made major treatment br...
Source: Molecular Biology Reports - Category: Molecular Biology Authors: Source Type: research
Bioorg Chem. 2021 Nov;116:105377. doi: 10.1016/j.bioorg.2021.105377. Epub 2021 Sep 17.ABSTRACTCDK4 &CDK6 are essential regulators of initial cell cycle phases and are always considered an exciting choice for anti-cancer therapy. In the present study, we presented the structure-based rational design &synthesis of a new class of 1,2,3-triazole tethered acridinedione derivatives (6a-l) as selective CDK4/6 inhibitors. Title molecules were prepared as a result of the rate-determining reaction between substituted derivatives of 1-Phenyl-1H-1,2,3-triazole-4-carbaldehydes and substituted dimedones, and the molecules were s...
Source: Bioorganic Chemistry - Category: Chemistry Authors: Source Type: research
An efficient autophagy suppressor is constructed for improving the therapeutic effect of low-dose photodynamic therapy, which can perform photoactivated burst release of oligonucleotide drug by self-disassembly of DNA nanostructure to achieve amplifiedATG5 gene silencing for enhancing antitumor effect. AbstractLow-dose photodynamic therapy (PDT) holds great promise for reducing undesired patient photosensitivity in cancer treatment. Yet, its therapeutic effect is significantly affected by intracellular cytoprotective processes, such as autophagy. Here, an efficient autophagy suppressor is developed, which is a multifunctio...
Source: Small - Category: Nanotechnology Authors: Tags: Research Article Source Type: research
This study reports a lack of radiosensitization in response to REV1 inhibition by small molecule inhibitors in ionizing radiation-exposed cancer cells. Instead, REV1 inhibition unexpectedly triggers autophagy, which is a known biomarker of radioresistance. We report a possible role of the REV1 TLS protein in determining cancer treatment outcomes depending upon the type of DNA damage inflicted. Furthermore, we discover that REV1 inhibition directly triggers autophagy, an uncharacterized REV1 phenotype, with a significant bearing on cancer treatment regimens.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
In this study, the nanoparticles of Fe3O4@Cu2–xS were rendered positively charged by conjugating their surfaces with different functional groups for strong electrostatic binding onto the negatively-charged cancer cells. In addition to the positively charged surfaces, the Fe3O4@Cu2–xS nanoparticles were also modified with folic acid (FA) for biomarker-based cell targeting. The dual-targeting approach synergistically utilizes the effectiveness of both charge- and biomarker-based cell binding for enhanced cell targeting. Further, these superparamagnetic Fe3O4@Cu2–xS nanoparticles exhibit much stronger IR abs...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
This commentary critically examines the modern paradigm of natural volatiles in ‘medical aromatherapy’, first by explaining the semantics of natural volatiles in health, then by addressing chemophenetic challenges to authenticity or reproducibility, and finally by elaborating on pharmacokinetic and pharmacodynamic processes in food, therapy, and disease prophylaxis. Research over the last 50 years has generated substantial knowledge of the chemical diversity of volatiles, and their strengths and weaknesses as antimicrobial agents. However, due to modest in vitro outcomes, the emphasis has shifted toward th...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Cancer Res. 2021 Oct 19:canres.1017.2021. doi: 10.1158/0008-5472.CAN-21-1017. Online ahead of print.ABSTRACTSystematic testing of existing drugs and their combinations is an attractive strategy to exploit approved drugs for repurposing and identify the best actionable treatment options. To expedite the search among many possible drug combinations, we designed a combinatorial CRISPR-Cas9 screen to inhibit druggable targets. Co-blockade of the N-methyl-D-aspartate receptor (NMDAR) with targets of first-line kinase inhibitors reduced hepatocellular carcinoma (HCC) cell growth. Clinically, HCC patients with low NMDAR1 expressi...
Source: Cell Research - Category: Cytology Authors: Source Type: research
Expert Opin Drug Saf. 2021 Oct 20. doi: 10.1080/14740338.2022.1996561. Online ahead of print.ABSTRACTINTRODUCTION: Cancer is considered one of the most devastating causes of death for humanity. Innovative and targeted therapies have become urgent in the treatment of this large subset of diseases. Over the last decade, the development of PARP (poly (ADP-Ribose) polymerase) inhibitors has emerged as a new target in cancer therapy.AREAS COVERED: The authors conducted a review focusing on the clinic relevance and adverse effects of the four drugs already approved by drug regulatory agencies, namely: olaparib, rucaparib, nirapa...
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Japan Health | Merck | Radiology | Study